Microbion
Clinical-stage pharmaceutical company developing a new class of antimicrobial compounds for local treatment of difficult-to-treat and antibiotic-resistant infections. The company's lead compound (INN: pravibismane) is being developed in topical/local and inhaled formulations, with preclinical characterization of mechanism of action (disruption of bacterial bioenergetics), in vitro and in vivo antimicrobial and antibiofilm testing, GLP toxicology / IND-enabling work, and ongoing Phase 1–2 clinical programs. The organization has secured multiple patents and regulatory designations and has received non-dilutive funding from public and philanthropic sources.
Industries
Nr. of Employees
small (1-50)
Patents
Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
US-11564903-B2
View Details
Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
US-11564903-B2
View DetailsProducts
Lead antimicrobial compound (INN: pravibismane)
First-in-class microbial bioenergetic inhibitor with broad-spectrum antimicrobial and antibiofilm activity being developed in topical/local and inhaled formulations for treatment of chronic wounds, orthopedic device-related infections, and pulmonary infections.
Lead antimicrobial compound (INN: pravibismane)
First-in-class microbial bioenergetic inhibitor with broad-spectrum antimicrobial and antibiofilm activity being developed in topical/local and inhaled formulations for treatment of chronic wounds, orthopedic device-related infections, and pulmonary infections.
Services
End-to-end development of anti-infective candidates including preclinical characterization, IND-enabling studies, regulatory filings, and early- to mid-stage clinical trials.
End-to-end development of anti-infective candidates including preclinical characterization, IND-enabling studies, regulatory filings, and early- to mid-stage clinical trials.
Expertise Areas
- Clinical trial management (Phase 1–2)
- Anti-infective drug development
- Biofilm research and antibiofilm therapeutics
- Topical and inhaled formulation development
Key Technologies
- CRISPR/Cas gene knockdown assays
- Minimum inhibitory concentration (MIC) testing
- Biofilm eradication and biofilm assays
- Intracellular infection cell-line assays (e.g., THP-1, A549)
News & Updates
Phase 2 study met primary safety endpoint and showed numerical efficacy trends including wound closure and wound-size reduction for topical high-concentration, 12-week regimens with primarily at-home dosing; no drug-attributable adverse events reported.
Peer-reviewed Phase 1b randomized, multicenter, double-blind, placebo-controlled trial reported safety and signals of efficacy (wound size reduction and lower amputation incidence) for topical administration.
FDA granted orphan drug designation for the lead compound for treatment of non-tuberculous mycobacterial infections; prior orphan designation existed for cystic fibrosis-related pulmonary infections.
Multiple US patents issued covering pharmaceutical compositions and methods of use for topical and inhaled administration, extending protection through 2039.
Received funding and awards from organizations including the Cystic Fibrosis Foundation, CARB-X, NIH, US DoD, and US Navy/MTEC (through CUBRC) to support IND-enabling studies, preclinical work, and Phase 2 clinical trials.
Phase 2 study met primary safety endpoint and showed numerical efficacy trends including wound closure and wound-size reduction for topical high-concentration, 12-week regimens with primarily at-home dosing; no drug-attributable adverse events reported.
Peer-reviewed Phase 1b randomized, multicenter, double-blind, placebo-controlled trial reported safety and signals of efficacy (wound size reduction and lower amputation incidence) for topical administration.
FDA granted orphan drug designation for the lead compound for treatment of non-tuberculous mycobacterial infections; prior orphan designation existed for cystic fibrosis-related pulmonary infections.
Multiple US patents issued covering pharmaceutical compositions and methods of use for topical and inhaled administration, extending protection through 2039.
Received funding and awards from organizations including the Cystic Fibrosis Foundation, CARB-X, NIH, US DoD, and US Navy/MTEC (through CUBRC) to support IND-enabling studies, preclinical work, and Phase 2 clinical trials.